DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Wealthfront Advisers LLC

Wealthfront Advisers LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 64.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,524 shares of the medical device company's stock after selling 17,309 shares during the quarter. Wealthfront Advisers LLC's holdings in DexCom were worth $650,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC increased its stake in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the period. Optiver Holding B.V. purchased a new stake in DexCom in the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC increased its position in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth approximately $38,000. Finally, Alpine Bank Wealth Management purchased a new position in shares of DexCom during the 1st quarter worth approximately $40,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,190 shares of company stock valued at $2,281,732. Corporate insiders own 0.32% of the company's stock.

DexCom Trading Up 0.4%

DXCM traded up $0.31 during trading on Thursday, hitting $86.74. The company's stock had a trading volume of 1,994,365 shares, compared to its average volume of 2,756,788. The stock has a market cap of $34.01 billion, a PE ratio of 64.73, a PEG ratio of 1.84 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $112.55. The firm's 50 day moving average price is $84.51 and its 200-day moving average price is $80.34.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. The company's revenue was up 12.5% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on DXCM shares. Robert W. Baird decreased their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley raised their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. The Goldman Sachs Group started coverage on shares of DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 target price on the stock. Piper Sandler reduced their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Finally, Barclays boosted their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $99.60.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.